{"schema_version":"secwatch.filing_event.v1","accession":"0001193805-23-001054","form_type":"8-K","ticker":"IMUX","cik":"0001280776","company_name":"IMMUNIC, INC.","filed_at":"2023-08-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.420620+00:00","generated_at":"2026-06-12T07:23:23.743910+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Immunic Q2 2023 net loss $24.0M; cash $77.3M funds into Q4 2024","bullets":["Net loss of $24.0M ($0.54/share) vs $21.9M ($0.72/share) in Q2 2022.","Cash, cash equivalents and investments at $77.3M as of June 30, 2023.","R&D expenses $21.2M, up from $16.5M YoY, driven by MS and IMU-856 programs.","Interim CALLIPER trial data in progressive MS expected fall 2023; ENSURE top-line late 2024.","Positive Phase 1b IMU-856 data in celiac disease; Phase 2 in active celiac being prepared."],"urls":{"canonical":"https://secwatch.observer/filing/0001193805-23-001054","json":"https://secwatch.observer/filing/0001193805-23-001054.json","markdown":"https://secwatch.observer/filing/0001193805-23-001054.md","text":"https://secwatch.observer/filing/0001193805-23-001054.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1280776/000119380523001054/0001193805-23-001054-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1280776/000119380523001054/e618816_8k-immunic.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T07:23:23.743910+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"95dee292e630c3eefed0c76da3704d2db9cf4f24","claim":"IMMUNIC, INC. reported financial results for the quarter ended June 30, 2023.","evidence_excerpt":"On August 3, 2023, Immunic, Inc. (the \"Company\") issued a press release announcing its financial results for the quarter ended June 30, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380523001054/0001193805-23-001054-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}